Biosimilars Rheumatology Roundup: June 2025

July 01, 2025

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and real-world efficacy insights.

Adalimumab Double Take: The Unexpected Return to Reference Humira

June 30, 2025

Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial Hurdles

June 29, 2025

The Top 5 Biosimilar Articles for the Week of June 23

June 27, 2025

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Review Finds 7 Themes That Can Help Define the Value of Biosimilars

June 10th 2024

By Skylar Jeremias

Article

Authors of an integrated literature review identified 7 themes that help stakeholders define the value of biosimilar portfolios beyond cost savings, which could provide stakeholders better clarity as to the value of a biosimilar portfolio vs a single biosimilar within a portfolio.

Dr Lakesha Farmer Highlights Current Biosimilar Education, Acceptance Efforts

June 9th 2024

By Ashley Gallagher

Video

Cencora's Lakesha Farmer, PharmD, MBA, discusses efforts that health care organizations can take to better educate patients and providers on biosimilars to improve biosimilar acceptance and achieve cost savings associated with these products.

Switching Patients With IBD to Infliximab, Adalimumab Biosimilars Did Not Impact Efficacy

June 8th 2024

By Deana Ferreri, PhD

Article

Researchers reviewed real-world evidence on the safety and effectiveness of switching from tumor necrosis factor-α inhibitor originators to biosimilars in inflammatory bowel disease (IBD), prompted by mandatory switching policies in most Canadian provinces.

The Top 5 Biosimilar Articles for the Week of June 3

June 7th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 3, 2024.

Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships

June 6th 2024

By Skylar Jeremias

Article

American and European regulatory agencies have provided companies with good news, with several biosimilar candidates seeing application acceptances or approvals in Europe.

ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars

June 5th 2024

By Skylar Jeremias

Article

Posters from the American Society of Clinical Oncology (ASCO) 2024 annual meeting demonstrate positive safety and efficacy data for denosumab and pegfilgrastim biosimilars.

Biosimilars Council Position Paper Calls for End to Clinical Efficacy Trials for Biosimilars

June 4th 2024

By Skylar Jeremias

Article

In a position paper from the Biosimilars Council, the organization points to evidence showing that clinical efficacy trials are a major barrier to biosimilar access in the US, calling for the FDA to change its policies to remove them in favor of other comparators.

BioRationality: FDA Updates Its Biosimilars Action Plan—A Major Step in Bringing More Biosimilars to Patients

June 3rd 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, analyzes updates to the FDA's Biosimilars Action Plan, as well as the agency's increased efforts to boost biosimilar adoption and education.

Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition

June 2nd 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.

Posters Capture Clinical Impacts of Infliximab in Super-Responders, Pregnant Patients With IBD

June 1st 2024

By Skylar Jeremias

Article

Posters from Digestive Disease Week 2024 look at how super-responders and pregnant patients with inflammatory bowel disease (IBD) react to treatment with subcutaneous infliximab and an infliximab biosimilar, respectively.